UBS Group Initiates Coverage on West Pharmaceutical Services (NYSE:WST)

Equities research analysts at UBS Group initiated coverage on shares of West Pharmaceutical Services (NYSE:WST) in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $415.00 price target on the medical instruments supplier’s stock. UBS Group’s target price indicates a potential upside of 22.50% from the company’s previous close.

WST has been the subject of a number of other research reports. Morgan Stanley lifted their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Wolfe Research started coverage on shares of West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 price target for the company. KeyCorp lifted their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. Finally, TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $373.85.

West Pharmaceutical Services Stock Performance

Shares of WST traded up $1.03 during trading hours on Wednesday, reaching $338.79. 23,467 shares of the company traded hands, compared to its average volume of 840,700. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The business has a fifty day moving average price of $349.83 and a 200-day moving average price of $308.63. West Pharmaceutical Services has a 12-month low of $223.83 and a 12-month high of $386.00. The stock has a market capitalization of $23.84 billion, a P/E ratio of 43.49, a P/E/G ratio of 2.38 and a beta of 1.14.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The company had revenue of $872.30 million during the quarter, compared to analysts’ expectations of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm’s revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities analysts anticipate that West Pharmaceutical Services will post 8.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. National Pension Service grew its holdings in West Pharmaceutical Services by 3,080.6% in the second quarter. National Pension Service now owns 126,271 shares of the medical instruments supplier’s stock valued at $45,331,000 after purchasing an additional 122,301 shares during the period. Engineers Gate Manager LP grew its stake in West Pharmaceutical Services by 486.9% in the 2nd quarter. Engineers Gate Manager LP now owns 18,868 shares of the medical instruments supplier’s stock valued at $6,774,000 after acquiring an additional 15,653 shares during the period. NewEdge Advisors LLC increased its holdings in West Pharmaceutical Services by 1.9% in the 2nd quarter. NewEdge Advisors LLC now owns 2,760 shares of the medical instruments supplier’s stock worth $991,000 after acquiring an additional 51 shares in the last quarter. Arizona State Retirement System raised its position in West Pharmaceutical Services by 5.6% during the second quarter. Arizona State Retirement System now owns 20,649 shares of the medical instruments supplier’s stock worth $7,413,000 after acquiring an additional 1,100 shares during the period. Finally, Empirical Finance LLC raised its position in West Pharmaceutical Services by 3.5% during the second quarter. Empirical Finance LLC now owns 2,501 shares of the medical instruments supplier’s stock worth $898,000 after acquiring an additional 85 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.